{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T03:55:05Z","timestamp":1785038105875,"version":"3.55.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2020,5,24]],"date-time":"2020-05-24T00:00:00Z","timestamp":1590278400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,5,24]],"date-time":"2020-05-24T00:00:00Z","timestamp":1590278400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA 182526"],"award-info":[{"award-number":["R01 CA 182526"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA022453"],"award-info":[{"award-number":["P30CA022453"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008457","name":"University of Virginia","doi-asserted-by":"crossref","award":["Startup Funds"],"award-info":[{"award-number":["Startup Funds"]}],"id":[{"id":"10.13039\/100008457","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100008457","name":"University of Virginia","doi-asserted-by":"crossref","award":["University of Virginia"],"award-info":[{"award-number":["University of Virginia"]}],"id":[{"id":"10.13039\/100008457","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1007\/s00432-020-03260-4","type":"journal-article","created":{"date-parts":[[2020,5,24]],"date-time":"2020-05-24T14:02:22Z","timestamp":1590328942000},"page":"2007-2016","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Enhanced cytotoxicity against solid tumors by bispecific antibody-armed CD19 CAR T cells: a proof-of-concept study"],"prefix":"10.1007","volume":"146","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3876-9555","authenticated-orcid":false,"given":"Archana","family":"Thakur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Scholler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana L.","family":"Schalk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl H.","family":"June","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence G.","family":"Lum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,24]]},"reference":[{"key":"3260_CR1","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1158\/2326-6066.CIR-13-0170","volume":"2","author":"GL Beatty","year":"2014","unstructured":"Beatty GL et al (2014) Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Cancer Immunol Res 2:112\u2013120","journal-title":"Cancer Immunol Res"},{"key":"3260_CR3","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1056\/NEJMoa1106152","volume":"365","author":"A Di Stasi","year":"2011","unstructured":"Di Stasi A, Tey SK, Dotti G, Fujita Y, Kennedy-Nasser A, Martinez C et al (2011) Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med 365:1673\u20131683","journal-title":"N Engl J Med"},{"key":"3260_CR4","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1158\/1078-0432.CCR-05-2005","volume":"12","author":"RC Grabert","year":"2006","unstructured":"Grabert RC, Cousens LP, Smith JA, Olson S, Gall J, Young WB, Davol PA, Lum LG (2006) Human T cells armed with Her2\/neu bispecific antibodies divide, are cytotoxic, and secrete cytokines with repeated stimulation. Clin Cancer Res 12:569\u2013576","journal-title":"Clin Cancer Res"},{"key":"3260_CR5","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","volume":"368","author":"SA Grupp","year":"2013","unstructured":"Grupp SA, Kalos M, Barrett D, Aplenc R, Porter D, Rheingold S et al (2013) Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 368:1509\u20131518","journal-title":"N Engl J Med"},{"issue":"37","key":"3260_CR6","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1146\/annurev-immunol-042718-041407","volume":"26","author":"S Guedan","year":"2019","unstructured":"Guedan S, Ruella M, June CH (2019) Emerging cellular therapies for cancer. Annu Rev Immunol 26(37):145\u2013171","journal-title":"Annu Rev Immunol"},{"key":"3260_CR7","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/mt.2013.17","volume":"14","author":"CH Lamers","year":"2013","unstructured":"Lamers CH, Sleijfer S, van Steenbergen S, van Elzakker P, van Krimpen B, Groot C et al (2013) Treatment of metastatic renal cell carcinoma With CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. Mol Ther 14:904\u2013912","journal-title":"Mol Ther"},{"issue":"6","key":"3260_CR2","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1089\/hgtb.2014.051","volume":"25","author":"CH Lamers","year":"2014","unstructured":"Lamers CH, van Steenbergen-Langeveld S, van Brakel M, Groot-van Ruijven CM, van Elzakker PM, van Krimpen B, Sleijfer S, Debets R (2014) T cell receptor-engineered T cells to treat solid tumors: T cell processing toward optimal T cell fitness. Hum Gene Ther Methods 25(6):345\u2013357","journal-title":"Hum Gene Ther Methods"},{"key":"3260_CR8","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1158\/1078-0432.CCR-14-2280","volume":"21","author":"LG Lum","year":"2015","unstructured":"Lum LG, Thakur A, Al-Kadhimi Z, Colvin GA, Cummings FJ, Legare RD, Dizon DS, Kouttab N, Maizel A, Colaiace W, Liu Q, Rathore R (2015) Targeted T-cell therapy in stage IV breast cancer: a phase I clinical trial. Clin Cancer Res 21:2305\u20132314","journal-title":"Clin Cancer Res"},{"key":"3260_CR9","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1056\/NEJMoa1103849","volume":"365","author":"DL Porter","year":"2011","unstructured":"Porter DL, Levine BL, Kalos M, Bagg A, June CH (2011a) Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 365:725\u2013733","journal-title":"N Engl J Med"},{"key":"3260_CR10","doi-asserted-by":"publisher","first-page":"331","DOI":"10.7150\/jca.2.331","volume":"2","author":"DL Porter","year":"2011","unstructured":"Porter DL, Kalos M, Zheng Z, Levine B, June C (2011b) Chimeric antigen receptor therapy for B-cell malignancies. J Cancer 2:331\u2013332","journal-title":"J Cancer"},{"issue":"1","key":"3260_CR11","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1158\/1078-0432.CCR-05-1855","volume":"12","author":"U Reusch","year":"2006","unstructured":"Reusch U, Sundaram M, Davol PA, Oson SD, Davis JB, Demel K, Nissim J, Rathore R, Liu PY, Lum LG (2006) Anti-CD3\u2009\u00d7\u2009anti-epidermal growth factor receptor (EGFR) bispecific antibody redirects T-cell cytolytic activity to EGFR-positive cancers in vitro and in an animal model. Clin Cancer Res 12(1):183\u2013190. https:\/\/doi.org\/10.1158\/1078-0432.CCR-05-1855","journal-title":"Clin Cancer Res"},{"issue":"2","key":"3260_CR12","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1089\/15258160151134944","volume":"10","author":"M Sen","year":"2001","unstructured":"Sen M et al (2001) Use of anti-CD3\u00a0\u00d7\u00a0anti-HER2\/neu bispecific antibody for redirecting cytotoxicity of activated T cells toward HER2\/neu\u2009+\u2009tumors. J Hematother Stem Cell Res 10(2):247\u2013260","journal-title":"J Hematother Stem Cell Res"},{"key":"3260_CR13","doi-asserted-by":"publisher","first-page":"e20","DOI":"10.1200\/JCO.2006.05.9964","volume":"24","author":"S Sleijfer","year":"2006","unstructured":"Sleijfer S, Vulto AG, Kruit WH, Kliffen M, Debets R et al (2006) Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J Clin Oncol 24:e20\u2013e22","journal-title":"J Clin Oncol"},{"key":"3260_CR14","doi-asserted-by":"publisher","first-page":"e1500672","DOI":"10.1080\/2162402X.2018.1500672","volume":"7","author":"A Thakur","year":"2018","unstructured":"Thakur A, Rathore R, Kondadasula SV, Uberti JP, Ratanatharathorn V, Lum LG (2018) Immune T cells can transfer and boost anti-breast cancer immunity. Oncoimmunology 7:e1500672","journal-title":"Oncoimmunology"},{"issue":"3","key":"3260_CR15","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1006\/clin.1994.1034","volume":"70","author":"JP Uberti","year":"1994","unstructured":"Uberti JP, Joshi I, Ueda M, Martilotti F, Sensenbrenner LL, Lum LG (1994) Preclinical studies using immobilized OKT3 to activate human T cells for adoptive immunotherapy: optimal conditions for the proliferation and induction of non-MHC-restricted cytotoxicity. Clin Immunol Immunopathol 70(3):234\u2013240","journal-title":"Clin Immunol Immunopathol"},{"issue":"2","key":"3260_CR16","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1097\/00007890-199308000-00019","volume":"56","author":"M Ueda","year":"1993","unstructured":"Ueda M, Joshi ID, Dan M, Uberti JP, Chou TH, Sensenbrenner LL, Lum LG (1993) Preclinical studies for adoptive immunotherapy in bone marrow transplantation, Generation of anti-CD3 activated cytotoxic T cells from normal donors and autologous bone marrow transplant candidates. Transplantation 56(2):351\u2013356","journal-title":"Transplantation"},{"key":"3260_CR17","doi-asserted-by":"publisher","first-page":"285193","DOI":"10.1155\/2015\/285193","volume":"2015","author":"U Vaishampayan","year":"2015","unstructured":"Vaishampayan U, Thakur A, Rathore R, Kouttab N, Lum LG (2015) Phase I study of anti-CD3\u00a0\u00d7\u00a0anti-Her2 bispecific antibody in metastatic castrate resistant prostate cancer patients. Prostate Cancer 2015:285193","journal-title":"Prostate Cancer"},{"key":"3260_CR18","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.3389\/fimmu.2018.02486","volume":"9","author":"K Watanabe","year":"2018","unstructured":"Watanabe K, Kuramitsu S, Posey AD Jr, June CH (2018) Expanding the therapeutic window for CAR T cell therapy in solid tumors: the knowns and unknowns of CAR T cell biology. Front Immunol 9:2486","journal-title":"Front Immunol"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-020-03260-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-020-03260-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-020-03260-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,23]],"date-time":"2021-05-23T23:19:10Z","timestamp":1621811950000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-020-03260-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,24]]},"references-count":18,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["3260"],"URL":"https:\/\/doi.org\/10.1007\/s00432-020-03260-4","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,24]]},"assertion":[{"value":"29 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"LGL is co-founder of <i>Transtarget<\/i> Inc. and serves on the SAB for Rapa Therapeutics, CHJ is a co-founder of <i>Tmunity Therapeutics<\/i>, Inc. and AT is co-founder of <i>Nova Immune Platform LLC,<\/i> JS and DLS have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}